GET DAILY SIGNALSDiaMedica Therapeutics (DMAC): Q3 2026 Preview Centers on ReMEDy2 Trial Momentum
Key Takeaways
- DiaMedica Therapeutics (NASDAQ: DMAC), a clinical-stage biopharmaceutical company, is expected to report third-quarter 2026 results in mid-November 2026.
- As a development-stage drugmaker with no marketed products, the company is expected to post zero revenue and a net loss per share of roughly -$0.21, in line with its recent run-rate.
- Investor attention is centered less on the income statement and more on clinical progress, particularly enrollment and timing for the ReMEDy2 stroke trial.
- Management has signaled a key interim efficacy readout for ReMEDy2 in the first quarter of 2027, making near-term trial updates a major watch item.
- With about $43.5 million in cash and investments reported as of the prior quarter, the company has guided that its balance sheet can fund operations into 2027.
Earnings Context and Its Relevance
DiaMedica Therapeutics develops DM199, a recombinant protein candidate aimed at acute ischemic stroke along with certain cardiovascular and kidney conditions. Without approved products on the market, its quarterly results mainly reflect spending patterns rather than sales. This makes the upcoming report useful primarily for insights into clinical momentum and the company's capital position. The third-quarter update comes as the lead ReMEDy2 stroke study moves closer to an interim efficacy analysis slated for the first quarter of 2027. For investors, the release serves as a checkpoint on trial timelines, cash burn rates, and whether expense guidance stays on track ahead of what could be a pivotal data point.
Expected Financial Results
Wall Street anticipates no product revenue for the third quarter of 2026 given the company's clinical-stage profile. Consensus estimates call for a net loss of about -$0.21 per share, a slight increase from the -$0.19 per share posted in the second quarter of 2026. Management has noted that quarterly losses may widen modestly as clinical programs progress, with prior guidance pointing to roughly -$0.21 per share near term and somewhat larger losses later.
Instead of revenue figures, focus is likely to fall on research and development expense trends. Those costs rose about 41% year over year to roughly $8.2 million in the second quarter as trial activity picked up. Other items to monitor include the cash and investments balance plus any fresh comments on the cash runway, which management has stated should cover operations into 2027. I also checked this using Tickeron’s AI Screener to compare spending patterns with peers.
Market Reaction and Sentiment Trends
Sentiment ahead of the third-quarter report has been driven mainly by clinical catalysts rather than financial metrics. DMAC shares have tended to show contained moves around earnings, which fits the pattern for a pre-revenue biotech where quarterly numbers carry limited headline impact. The stock posted modest gains after the second-quarter 2026 report, which aligned with consensus on the bottom line and included positive early data from a late-onset preeclampsia study along with solid enrollment progress in ReMEDy2.
Key risks to watch include the pace of trial enrollment, any shifts in projected timelines for the interim analysis, and cash burn relative to the guided runway. Investors will also monitor for signs that development costs are rising faster than expected, which could pressure the stock even without new clinical data.
Forward Outlook and Items to Track
Beyond the third-quarter print, the main catalyst remains the ReMEDy2 Phase 2/3 trial in acute ischemic stroke, with an interim efficacy analysis expected in the first quarter of 2027. Management has noted that the trial has passed the 85% enrollment milestone, and investors will seek confirmation that enrollment completion and the data readout stay on schedule.
Separately, the company continues to advance its late-onset preeclampsia program, which recently showed statistically significant blood pressure reduction in a clinical study. First patient dosing in a Canadian preeclampsia study is planned for the fourth quarter of 2026, offering another near-term milestone. From a financial perspective, attention will stay on R&D spending trends and the cash balance. DMAC ended the second quarter with roughly $43.5 million in cash and investments and has guided that this supports operations into 2027. Any notable acceleration in expenses or commentary pointing to a shorter runway would stand out alongside the clinical timeline. From what I see, steady execution here remains central.
AI Tools in My Research Process
I regularly turn to Tickeron’s AI Screener when screening clinical-stage biotechs and comparing sector peers on fundamentals and technical signals. It helps surface relevant names and monitor watchlists more efficiently during periods like this earnings window.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DMAC's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for DMAC turned positive on October 22, 2026. Looking at past instances where DMAC's MACD turned positive, the stock continued to rise in 48 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMAC as a result. In 78 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 219 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 133 of 159 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for DMAC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 58 cases where DMAC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
DMAC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 33 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.166) is normal, around the industry mean (3.498). P/E Ratio (-13.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapeutic compounds for diabetes and other diseases
Industry Biotechnology